Chronic myeloid leukemia in the tyrosine kinase inhibitor era: What is the best therapy?

Current Oncology Reports

Volumn 11, Issue 5, 2009, Pages 337-345

  Quintás Cardama, Alfonso ^b   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AP 24534; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; DC 2036; DCC 2036; IMATINIB; NILOTINIB; OMACETAXINE; PHA 739538; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; XL 228;

ANTINEOPLASTIC ACTIVITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DISEASE DURATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EVENT FREE SURVIVAL; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOPHOSPHATEMIA; IC 50; NEUTROPENIA; PANCREATITIS; PLEURA EFFUSION; POINT MUTATION; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QT PROLONGATION; REVIEW; SIDE EFFECT; SYNCOPE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT RESPONSE;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES; TREATMENT OUTCOME;

EID: 68949096693     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0046-y     Document Type: Review

References (53)

1. Druker BJ, Guilhot F, O'Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
2. O'Brien SG, Guilhot F, Goldman J, et al.: International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: Sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) [abstract]. Blood 2008, 112:186.
3. O'Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348:994-1004.
4. Hughes TP, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
5. Cortes J, Talpaz M, O'Brien S, et al.: Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005, 11:3425-3432.
6. de Lavallade H, Apperley JF, Khorashad JS, et al.: Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intentionto-treat analysis. J Clin Oncol 2008, 26:3358-3363.
7. Quintás-Cardama A, Kantarjian HM, Cortes JE: Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009, 16:122-131.
8. Weisberg E, Manley PW, Cowan-Jacob SW, et al.: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007, 7:345-356.
9. Larson RA, Druker BJ, Guilhot F, et al.: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
10. Picard S, Titier K, Etienne G, et al.: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
11. Druker BJ, Sawyers CL, Kantarjian H, et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001, 344:1038-1042.
12. Branford S, Rudzki Z, Harper A, et al.: Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia 2003, 17:2401-2409.
13. Kantarjian H, O'Brien S, Shan J, et al.: Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: Need for new response definitions? Cancer 2008, 112:837-845.
14. Quintás-Cardama A, Kantarjian H, Cortes J: Tyrosine kinase inhibitors for chronic myelogenous leukemia. New Engl J Med 2007, 357:1557; author reply 1558.
15. Kantarjian H, Talpaz M, O'Brien S, et al.: High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004, 103:2873-2878.
16. Cortes J, Giles F, O'Brien S, et al.: Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003, 102:83-86.
17. Hughes TP, Branford S, White DL, et al.: Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood 2008, 112:3965-3973.
18. Cortes J, Baccarani M, Guilhot F, et al.: A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study [abstract]. Blood 2008, 112:335.
19. Baccarani M, Castagnetti F, Simonsson B, et al.: Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): Results of an European Leukemianet prospective study comparing 400 mg and 800 mg front-line [abstract]. Blood 2008, 112:185.
20. Jabbour E, Kantarjian HM, Jones D, et al.: Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009, 113:2154-2160.
21. Lombardo LJ, Lee FY, Chen P, et al.: Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin- 1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
22. Shah NP, Tran C, Lee FY, et al.: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305:399-401.
23. O'Hare T, Walters DK, Stoffregen EP, et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
24. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
25. Mauro M, Baccarani M, Cervantes F, et al.: Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol 2008, 26(May 20 Suppl):7009.
26. Rousselot P, Facon T, Paquette R, et al.: Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standarddose imatinib: 2-year follow-up data from START-R [abstract]. J Clin Oncol 2008, 26(May 20 Suppl):7012.
27. Shah N, Kim DW, Kantarjian H, et al.: Dasatinib doseoptimization in chronic phase chronic myeloid leukemia (CML-CP): Two-year data from CA180-034 show equivalent long-term efficacy and improved safety with 100 mg once daily dose [abstract]. Blood 2008, 112:3225.
28. Kantarjian H, Kim DW, Dorlhiac-Llacer P, et al.: Dasatinib 140 mg once daily demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily in patients with accelerated phase chronic myeloid leukemia: 2-year follow-up data from CA180-035 [abstract]. Blood 2008, 112:3224.
29. Saglio G, Kantarjian H, Hochhaus A, et al.: Dasatinib 140 mg once daily demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily in patients with chronic myeloid leukemia in blast phase: 2-year data from CA180-035 [abstract]. Blood 2008, 112:3226.
30. Weisberg E, Manley PW, Breitenstein W, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
31. Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
32. Kantarjian H, Giles F, Bhalla K, et al.: Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 2008, 112:3238.
33. Kantarjian HM, Giles F, Gattermann N, et al.: Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540-3546.
34. Le Coutre P, Giles F, Hochhaus A, et al.: Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood 2008, 112:3229.
35. Giles F, Larson RA, Kantarjian K, et al.: Nilotinib in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract]. Blood 2007, 110:1025.
36. Remsing Rix LL, Rix U, Colinge J, et al.: Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells. Leukemia 2009, 23:477-485.
37. Redaelli S, Piazza R, Rostagno R, et al.: Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009, 27:469-471.
38. Cortes J, Kantarjian H, Kim DW, et al.: Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib [abstract]. Blood 2008, 112:1098.
39. Gambacorti-Passerini C, Pogliani E, Baccarani M, et al.: Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL [abstract]. Blood 2008, 112:1101.
40. Rosti G, Castagnetti F, Poerio A, et al.: High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party [abstract]. Blood 2008, 112:181.
41. Cortes J, O'Brien S, Borthakur G, et al.: Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CMLCP) [abstract]. Blood 2008, 112:182.
42. Cortes J, O'Brien S, Jones D, et al.: Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood 2008, 112:446.
43. Quintás-Cardama A, Kantarjian H, Jones D, et al.: Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2007, 109:497-499.
44. Giles F, Le Coutre P, Bhalla K, et al.: Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) who failed prior imatinib and dasatinib therapy: Updated results of a phase 2 study [abstract]. Blood 2008, 112:3234.
45. Garg RJ, Kantarjian H, O'Brien SM, et al.: The use of 2nd generation tyrosine kinase inhibitors (TKI) after failure to 2 prior TKI: Long-term follow-up [abstract]. Blood 2008, 112:2119.
46. Kozopas KM, Yang T, Buchan HL, et al.: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A 1993, 90:3516-3520.
47. Chen Y, Hu Y, Michaels S, et al.: Inhibitory effects of homoharringtonine on leukemic stem cells and BCR-ABL induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice [abstract]. Blood 2007, 110:2912.
48. Quintás-Cardama A, Kantarjian H, Garcia-Manero G, et al.: Phase I/ II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007, 109:248-255.
49. Cortes J, Khoury HJ, Corm S, et al.: Safety and efficacy of subcutaneous (SC) omacetaxine mepesuccinate in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (pts) with the T315I mutation - results of an ongoing multicenter phase II study [abstract]. Blood 2008, 112:3239.
50. Cortes J, Paquette R, Talpaz M, et al.: Preliminary clinical activity in a phase I trial of the BCR-ABL/IGF-1R/Aurora kinase inhibitor XL228 in patients with Ph+ leukemias with either failure to multiple TKI therapies or with T315I mutation [abstract]. Blood 2008, 112:3232.
51. Paquette R, Shah N, Sawyers C, et al.: PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL [abstract]. Blood 2007, 110:1030.
52. O'Hare T, Eide CA, Adrian LT, et al.: Complete suppression of in vitro resistance by AP24534, a pan-BCR-ABL inhibitor [abstract]. Blood 2008, 112:726.
53. Van Etten RA, Chan WW, Zaleskas VM, et al.: Switch pocket inhibitors of the ABL tyrosine kinase: Distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I [abstract]. Blood 2008, 112:576.